论文部分内容阅读
目的探讨血管抑制素(Angiostatin,AS)和内皮抑制素(Endostatin,ES)在不同类型子宫内膜癌中的表达差异。方法采用免疫组化法检测AS和ES在75例子宫内膜样腺癌和26例非内膜样癌(粘液性腺癌6例、透明细胞癌7例、腺鳞癌8例、混合型腺癌5例)表达的差异及与临床预后的相关性。结果 AS和ES在子宫内膜样腺癌中高表达,阳性表达率分别达77.23%和72.00%,显著高于非内膜样癌组(26.92%和30.77%),差异有统计学意义(P<0.05);其中在非内膜样癌中,透明细胞型子宫内膜癌的阳性率最高,但与其他类型比较无统计学差异(P>0.05)。结论血管生长抑制素和内皮生长抑制素在子宫内膜样腺癌中高表达,且与患者预后密切相关,可作为预测患者疗效和预后的重要指标。
Objective To investigate the difference of expression of angiostatin (AS) and endostatin (ES) in different types of endometrial carcinoma. Methods Immunohistochemistry was used to detect the expression of AS and ES in 75 cases of endometrioid adenocarcinoma and 26 cases of non-endometrioid carcinoma (6 cases of mucinous adenocarcinoma, 7 cases of clear cell carcinoma, 8 cases of adenosquamous carcinoma, 2 cases of mixed adenocarcinoma 5 cases) and their correlation with clinical prognosis. Results The expression of AS and ES was high in endometrioid adenocarcinoma, with a positive rate of 77.23% and 72.00%, respectively, which was significantly higher than that in non-endometrioid carcinoma (26.92% and 30.77%, P < 0.05). The positive rate of clear cell endometrial carcinoma was the highest in non-endometrioid carcinoma, but no significant difference compared with other types (P> 0.05). Conclusions Angiostatin and endostatin are highly expressed in endometrial adenocarcinoma and are closely related to the prognosis of patients. They can be used as an important index to predict the efficacy and prognosis of patients.